The bioavailability problem Absorption comparison: Injection: 80-100% bioavailability (nearly all absorbed) Nasal spray: 30-70% bioavailability (varies by peptide) Oral: 0-5% bioavailability (most peptides destroyed) Why nasal lower than injection: Must penetrate nasal mucosa (barrier) Some drips down throat (swallowed = lost) Variable absorption efficiency Technique-dependent Individual variation high What this means: You need MORE peptide via nasal spray Typically 2-3x higher dose than injection Example: 1mg injection = 2-3mg nasal Increases cost significantly But still cheaper/easier than injection for some Conversion guidelines by peptide PT-141: Injection: 1.5-2mg typical dose Nasal equivalent: 3-5mg Conversion ratio: 2-3x Semax: Designed for nasal use (no conversion needed) Standard nasal dose: 200-600mcg per spray 2-3 sprays per nostril typical Follow product guidelines BPC-157 (if attempting nasal): Injection: 250-500mcg Nasal (estimated): 750-1500mcg But: Injection or oral likely better Nasal BPC-157 not well-studied General conversion approach: Start with 2-3x injection dose Assess results after 2-3 uses Increase by 25-50% if weak effects Find minimum effective nasal dose Individual variation significant Cost implications: Using 2-3x more peptide = 2-3x cost Nasal spray more expensive per dose Trade-off: Convenience vs cost Worth it for needle-phobic Not worth it if injections acceptable Use peptide cost calculator to compare routes
The protein has good GSH-transferase activity with CDNB, i.e
Teixidor-Deulofeu J, Blid Skldheden S, Font-Girons F, Feje A, Ruud J, Engstrm Ruud L, et al
Through Weight Watchers Med+ , members can access licensed clinicians who determine whether prescription treatments are appropriate
So, with little previous research in this area we were keen to understand why this was the case and to find out what impact there was on the safety of patients. She added: We believe there is an opportunity for healthcare professionals to encourage patients to come to them for advice as our research showed that 72% are finding information around medication from online, closed support groups
The FDA approved tirzepatide for chronic weight management on November 8, 2023, under the brand name Zepbound
